Specificity studies on the oligosaccharide neuraminidase of human fibroblasts.

Competition and thermal inactivation experiments with different potential natural substrates indicated that in homogenates of human fibroblasts one single enzyme is acting on both (alpha 2-3) and (alpha 2-6) sialosyl linkages of oligosaccharides and glycoproteins, but not of the ganglioside GM3. N-Acetylneuraminic and 2-deoxy-2,3-dehydro-N-acetylneuraminic acids are competitive inhibitors, whereas chondroitin 4-sulphate and the drug Suramin are potent inhibitors of undefined type.     

Specificity of action of neuraminidase, according to its bacteriological origin.

Neuraminidase from Vibrio Cholerae selectively cleaves sialic acid from FSH, but leaves the LH sialic acid, not influencing the biological activity of the latter hormone. On the other hand, Neuraminidase from Clostridium perfringens does not possess this specific action and destroys the biological activity of LH as is suggested by Parlow's OAAD-test.     

Specificity of a human leukocyte neutral proteinase with bovine parathyroid hormone as substrate

• 1.1. A neutral proteinase, located on the surface of human granulocytes and lymphocytes, degraded bovine parathyroid hormone in vitro.
• 2.2. The observed sites of cleavage were between residues 5 and 6 (—ile—gin—), 8 and 9 (—met—his—), 38 and 39 (—gly—ala—) and 41 and 42 (—ile—ala—). 3. Possible physiological implications of these findings are discussed.

     

Pneumococcal neuraminidase

Lee, L. T. (Columbia University, New York, N.Y.), and C. Howe. Pneumoccal neuraminidase. J. Bacteriol. 91:1418-1426. 1966.-The elaboration of neuraminidase by pneumococci grown under optimal conditions in liquid medium was studied in relation to the bacterial growth cycle. The enzyme was found free in the culture medium in increasing concentration throughout most of the logarithmic phase of growth, at the end of which enzyme concentration had reached a maximum. Only a small fraction of the total neuraminidase was cell-associated at any time. It appears, therefore, that pneumococcal neuraminidase is actively secreted by dividing cells and does not accumulate solely as a result of cellular autolysis. Neuraminidase in cell-free extracts (types I, III, VII, and XIV) was neutralized both by homotypic and by heterotypic antibody, thus demonstrating it to be a group antigen. The enzyme was separable in agar gel electrophoresis from other protein and polysaccharide pneumococcal antigens. Limited immunochemical data suggest that pneumococcal neuraminidase may be of relatively low molecular weight.     

BV三联法用于阴道用乳杆菌活菌胶囊产过氧化氢、唾液酸苷酶、白细胞酯酶的检测

目的 验证阴道用乳杆菌活菌胶囊的产过氧化氢、唾液酸苷酶、白细胞酯酶的能力.方法 用BV三联法检测阴道用乳杆菌活菌胶囊中的过氧化氢浓度、唾液酸苷酶、白细胞脂酶.结果 BV三联法检测阴道用乳杆菌,经发酵后过氧化氢反应为阴性,唾液酸苷酶和白细胞酯酶反应均为阴性.结论 利用BV三联法可以快速检测出阴道用乳杆菌活菌胶囊的产过氧化氢、唾液酸苷酶、白细胞酯酶的能力.     

Escherichia coli neuraminidase

The intracellular form of neuraminidase has been detected in E. coli and Proteus vulgaris. Neuraminidase has been isolated from E. coli HB 101 cells and purified 118-fold. Some physico-chemical properties of this enzyme have been studied.     

Human liver neuraminidase

Two neuraminidase activities have been found in normal human liver, one soluble and the other particulate and essentially bound to the lysosomes. With storage of the liver at ?80°C, no loss of either type of activity was noted for up to a year. KCl extracts of the soluble enzyme were stable for 15 days when stored in liquid nitrogen. For the sediments (particulate or lysosomal), almost 100% of the initial activity was recovered after up to a month's storage at ?20°C. With neuramine-lactose as substrate, the pH optimum was 4.0 for the soluble, particulate and lysosomal enzymes. The Km values were 8.0 × 10^?3M for the soluble neuraminidase and 16.66 × 10^?3M and 16.95 × 10^?3M for the light and heavy lysosomal neuraminidases, respectively. The results suggest that normal human liver contains a single neuraminidase which may exist in either soluble form or incorporated in a membrane structure, depending on the condition of donor. The differences in behaviour could be explained in terms of “allotopic” properties.     

Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses

Neuraminidase inhibitors (NAIs) are antivirals designed to target conserved residues at the neuraminidase (NA) enzyme active site in influenza A and B viruses. The conserved residues that interact with NAIs are under selective pressure, but only a few have been linked to resistance. In the A/Wuhan/359/95 (H3N2) recombinant virus background, we characterized seven charged, conserved NA residues (R118, R371, E227, R152, R224, E276, and D151) that directly interact with the NAIs but have not been reported to confer resistance to NAIs. These NA residues were replaced with amino acids that possess side chains having similar properties to maintain their original charge. The NA mutations we introduced significantly decreased NA activity compared to that of the A/Wuhan/359/95 recombinant wild-type and R292K (an NA mutation frequently reported to confer resistance) viruses, which were analyzed for comparison. However, the recombinant viruses differed in replication efficiency when we serially passaged them in vitro; the growth of the R118K and E227D viruses was most impaired. The R224K, E276D, and R371K mutations conferred resistance to both zanamivir and oseltamivir, while the D151E mutation reduced susceptibility to oseltamivir only (approximately 10-fold) and the R152K mutation did not alter susceptibility to either drug. Because the R224K mutation was genetically unstable and the emergence of the R371K mutation in the N2 subtype is statistically unlikely, our results suggest that only the E276D mutation is likely to emerge under selective pressure. The results of our study may help to optimize the design of NAIs.     

Properties of human chorion neuraminidase

Some properties of human chorion neuraminidase were studied. Using n-butanol, a solubilized preparation of neuraminidase with specific activity considerably exceeding the initial activity of the chorion homogenate was obtained. The pH-dependence and substrate specificity of the enzyme towards low molecular weight (sialylglycolipids and sialylglycoproteins) native substrates were examined. These properties of solubilized neuraminidase from human chorion were found to be similar to those of the lysosomal enzyme from other animal tissues. The results abtained are consistent with the properties of neuraminidase from native chorion and amniotic fluid cell cultures. Based on the substrate specificity of the solubilized enzyme, it was found that chorion biopsy specimens could be used for prenatal diagnosing of sialidoses and mucolipidoses IV. Some properties of solubilized human chorion beta-galacotosidase were studied.     

The neuraminidase of influenza virus

It is the enzyme neuraminidase, projecting from the surface of influenza virus particles, which allows the virus to leave infected cells and spread in the body. Antibodies which inhibit the enzyme limit the infection, but antigenic variation of the neuraminidase renders it ineffective in a vaccine. This article describes the crystal structure of influenza virus neuraminidase, information about the active site which may lead to development of specific and effective inhibitors of the enzyme, and the structure of epitopes (antigenic determinants) on the neuraminidase. The 3-dimensional structure of the epitopes was obtained by X-ray diffraction methods using crystals of neuraminidase complexed with monoclonal antibody Fab fragments. Escape mutants, selected by growing virus in the presence of monoclonal antibodies to the neuraminidase, possess single amino acid sequence changes. The crystal structure of two mutants showed that the change in structure was restricted to that particular sidechain, but the change in the epitope was sufficient to abolish antibody binding even though it is known in one case that 21 other amino acids on the neuraminidase are in contact with the antibody.     

Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes

The viral neuraminidase enzyme is an established target for anti-influenza pharmaceuticals. However, viral neuraminidase inhibitors could have off-target effects due to interactions with native human neuraminidase enzymes. We report the activity of a series of known inhibitors of the influenza group-1 neuraminidase enzyme (N1 subtype) against recombinant forms of the human neuraminidase enzymes NEU3 and NEU4. These inhibitors were designed to take advantage of an additional enzyme pocket (known as the 150-cavity) near the catalytic site of certain viral neuraminidase subtypes (N1, N4 and N8). We find that these modified derivatives have minimal activity against the human enzymes, NEU3 and NEU4. Two compounds show moderate activity against NEU3, possibly due to alternative binding modes available to these structures. Our results reinforce that recognition of the glycerol side-chain is distinct between the viral and human NEU enzymes, and provide experimental support for improving the selectivity of viral neuraminidase inhibitors by exploiting the 150-cavity found in certain subtypes of viral neuraminidases.     

Characterization of influenza virus neuraminidase with hemagglutinin activity and its comparison with that of viral neuraminidase

The neuraminidase associated with the bifunctional protein, hemagglutinin-neuraminidase, of influenza virus has been characterized. The enzyme has a pH optimum of 4.5, does not require Ca2+ and is inactivated (98%) by incubation at 50 degrees C. The enzyme has a Km of 2.00 X 10(-3) M and 0.06 X 10(-3) M with the substrates 2-(3-methoxyphenyl)-N-acetylneuraminic acid and fetuin, respectively. The Ki is 400 X 10(-6) with the inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. The incorporation of labeled cysteine, valine and leucine in the hemagglutinin-neuraminidase protein is different from that of viral neuraminidase. A comparison of the properties of the neuraminidase associated with protein hemagglutinin-neuraminidase with that of viral neuraminidase or sialidase showed that the former is biochemically different and an antigenically distinct enzyme. The unique feature of the new enzyme is that it has the hemagglutinin activity as well. The two biological activities could not be separated from each other in all systems used. Apparently, protein hemagglutinin-neuraminidase is genetically transferable and it is detectable in a laboratory recombinant virus E-2971 (H3 Aichi X N7). These results suggest that protein hemagglutinin-neuraminidase is a unique surface protein of the influenza virus A/Aichi/2/68 (H3N2).